K. Brunden

发表

ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models

Donald A. Wilson, D. Wesson, G. Landreth, 2012, Science.

Microtubule-Stabilizing Agents for Alzheimer’s and Other Tauopathies

J. Trojanowski, V. Lee, Amos B. Smith, 2016 .

Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies

J. Trojanowski, V. Lee, Amos B. Smith, 2014, Journal of medicinal chemistry.

Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

J. Trojanowski, V. Lee, Amos B. Smith, 2014, Bioorganic & medicinal chemistry.

Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.

B. Sherf, K. Brunden, Steven M. Murphy, 2006, Journal of pharmacological and toxicological methods.

GPRC6A Null Mice Exhibit Osteopenia, Feminization and Metabolic Syndrome

Ling Chen, P. Jackson, L. Quarles, 2008, PloS one.

Isolation of an integral membrane glycoprotein by chloroform-methanol extraction and C3-reversed-phase high-performance liquid chromatography.

K. Brunden, J. Poduslo, C. Berg, 1987, Analytical biochemistry.

pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans.

K. Brunden, R. Frederickson, N. J. Richter-Cook, 1993, Journal of neurochemistry.

Purification of a small receptor-binding peptide from the central region of the colicin E1 molecule.

F. S. Cohen, W. Cramer, K. Brunden, 1984, The Journal of biological chemistry.

Acidic pH requirement for insertion of colicin E1 into artificial membrane vesicles: relevance to the mechanism of action of colicins and certain toxins.

V. Davidson, W. Cramer, K. Brunden, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of multiple forms of the human glycine transporter type-2.

K. Brunden, L. H. Burgess, M. J. Gallagher, 1999, Brain research. Molecular brain research.

Myelin protein expression in dissociated superior cervical ganglia and dorsal root ganglia cultures

Y. Ding, K. Brunden, B. S. Hennington, 1992, Journal of neuroscience research.

Evidence for glial-mediated inflammation in aged APPSW transgenic mice

W. Benzing, S. Younkin, K. Ashe, 1999, Neurobiology of Aging.

1,2,4-Triazolo[1,5-a]pyrimidines in drug design.

K. Brunden, C. Ballatore, Killian Oukoloff, 2019, European journal of medicinal chemistry.

well as regulated genes be identified? high store-operated calcium entry: can regulatory as Gene expression profiles in HEK-293 cells with low or

Arpad M. Danos, K. Brunden, L. Volpicelli-Daley, 2015 .

Characterization of tau binding by gosuranemab

J. Trojanowski, V. Lee, Richelle Sopko, 2020, Neurobiology of Disease.

Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy

J. Trojanowski, V. Lee, Amos B. Smith, 2016, Acta Neuropathologica Communications.

Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.

J. Trojanowski, V. Lee, K. Brunden, 2012, Biochemical Society transactions.

Characterization of tau fibrillization in vitro

J. Trojanowski, V. Lee, Shaohua Xu, 2010, Alzheimer's & Dementia.

Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies.

K. Brunden, J. B. Parent, R. Gupta-Bansal, 2000, Molecular immunology.

Po mRNA expression in cultures of Schwann cells and neurons that lack basal lamina and myelin

K. Brunden, D. T. Brown, 1990, Journal of neuroscience research.

Brain‐Penetrant Triazolopyrimidine and Phenylpyrimidine Microtubule Stabilizers as Potential Leads to Treat Human African Trypanosomiasis

Amos B. Smith, C. Caffrey, K. Brunden, 2018, ChemMedChem.

Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

J. Trojanowski, V. Lee, D. Huryn, 2012, Journal of medicinal chemistry.

Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation

Bin Zhang, John Q Trojanowski, Ted Abel, 2017, Nature Medicine.

3-Indolyl sultams as selective CRTh2 antagonists.

R. Mays, D. Hanniford, B. Sherf, 2010, Bioorganic & medicinal chemistry letters.

Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists.

N. Varga, R. Mays, D. Hanniford, 2005, Bioorganic & medicinal chemistry letters.

Activated Neuroglia in Alzheimer’s Disease

K. Brunden, R. Frederickson, 2002 .

Aβ-Induced Proinflammatory Cytokine Release from Differentiated Human THP-1 Monocytes.

S. L. Yates, K. Brunden, P. Embury, 2000, Methods in molecular medicine.

Congo Red Inhibits Proteoglycan and Serum Amyloid P Binding to Amyloid β Fibrils

K. Brunden, R. Gupta-Bansal, 1998 .

Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies.

J. Trojanowski, V. Lee, A. Brancale, 2021, Journal of medicinal chemistry.

Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines.

J. Trojanowski, V. Lee, Michael J. James, 2018, Bioorganic & Medicinal Chemistry Letters.

brain-penetrant enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.

Virginia M. Y. Lee, J. Trojanowski, Amos B. Smith, 2018 .

Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies.

J. Trojanowski, V. Lee, Amos B. Smith, 2017, ACS chemical neuroscience.

Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer’s Disease and Related Tauopathies

J. Trojanowski, V. Lee, Amos B. Smith, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine.

J. Trojanowski, V. Lee, Amos B. Smith, 2015, Bioorganic & medicinal chemistry letters.

MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.

J. Trojanowski, V. Lee, Amos B. Smith, 2013, ACS medicinal chemistry letters.

Advancing Alzheimer's Diagnosis, Treatment and Care: Recommendations from the Ware Invitational Summit

R. Brookmeyer, J. Trojanowski, K. Blennow, 2013 .

Design of comprehensive Alzheimer's disease centers to address unmet national needs

Christos Davatzikos, Murray Grossman, Mary Naylor, 2010, Alzheimer's & Dementia.

Role of basal lamina in Schwann cell glycolipid biosynthesis

Jeffrey K. Yao, K. Brunden, R. Gregory, 1994, Neurochemical Research.

Role of axons in the regulation of PO biosynthesis by Schwann cells

A. Windebank, K. Brunden, J. Poduslo, 1990, Journal of neuroscience research.

Age‐Dependent Changes in the Oligosaccharide Structure of the Major Myelin Glycoprotein, P0

K. Brunden, 1992, Journal of neurochemistry.

A Phorbol Ester‐Sensitive Kinase Catalyzes the Phosphorylation of P0 Glycoprotein in Myelin

K. Brunden, J. Poduslo, Joseph F. Poduslo, 1987, Journal of neurochemistry.

Posttranslational Degradation of the Major Myelin Glycoprotein by Schwann Cells in Vivo and in Vitro a

K. Brunden, J. Poduslo, 1990, Annals of the New York Academy of Sciences.

IgM/IgG solid-phase antibody-capture assay with biotin/125I-streptavidin amplification: application to normal human sural nerve biopsies

P. Dyck, K. Brunden, G. Curran, 1988, Journal of Neuroimmunology.

Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.

J. Trojanowski, V. Lee, M. Hutton, 2011, Cold Spring Harbor perspectives in medicine.

Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties.

J. Trojanowski, V. Lee, Kevin Lou, 2012, Bioorganic & medicinal chemistry.

The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors.

B. Huck, A. Bailey, S. Rundlett, 2005, Bioorganic & medicinal chemistry letters.

The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitors.

B. Huck, A. Bailey, S. Rundlett, 2004, Bioorganic & Medicinal Chemistry Letters.

Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases

J. Trojanowski, V. Lee, Amos B. Smith, 2017, Journal of medicinal chemistry.

Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice

J. Trojanowski, V. Lee, A. de Bondt, 2021, Acta Neuropathologica Communications.

In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics

Jeffrey J. Nirschl, G. Schellenberg, J. Trojanowski, 2021, Acta Neuropathologica.

Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease

J. Trojanowski, Bin Zhang, K. Brunden, 2020, Molecular neurodegeneration.

Correction of microtubule defects within Aβ plaque‐associated dystrophic axons results in lowered Aβ release and plaque deposition

J. Trojanowski, V. Lee, K. Brunden, 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist.

B. Huck, K. Brunden, J. Harrington, 2006, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.

E. Novellino, A. Coluccia, A. Brancale, 2013, Journal of medicinal chemistry.

Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease.

J. Trojanowski, V. Lee, Amos B. Smith, 2012, ACS chemical neuroscience.

Chapter 11 – Microtubule Stabilization

J. Trojanowski, V. Lee, Amos B. Smith, 2016 .

Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy*♦

K. Brunden, L. Volpicelli-Daley, V. Lee, 2013, The Journal of Biological Chemistry.

Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation.

K. Brunden, R. Frederickson, R. Gupta-Bansal, 1995, The Journal of biological chemistry.

Structure Property Relationships of Carboxylic Acid Isosteres

D. Huryn, Amos B. Smith, M. Kozlowski, 2016, Journal of medicinal chemistry.

Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group.

J. Trojanowski, V. Lee, Amos B. Smith, 2014, Bioorganic & Medicinal Chemistry Letters.

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

J. Trojanowski, V. Lee, K. Brunden, 2016, Alzheimer's & Dementia.

Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group.

J. Trojanowski, V. Lee, Amos B. Smith, 2017, ACS medicinal chemistry letters.

Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists.

J. Trojanowski, V. Lee, D. Huryn, 2011, Journal of medicinal chemistry.

pH‐Dependent Binding of Synthetic β‐Amyloid Peptides to Glycosaminoglycans

K. Brunden, R. Frederickson, N. J. Richter-Cook, 1993 .

Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice

J. Trojanowski, V. Lee, M. Mercken, 2015, Neurobiology of Disease.

Congeners Derived from Microtubule-Active Phenylpyrimidines Produce a Potent and Long-Lasting Paralysis of Schistosoma mansoni In Vitro.

Amos B. Smith, C. Caffrey, K. Brunden, 2020, ACS infectious diseases.

Effects of TNFα-Converting Enzyme Inhibition on Amyloid β Production and APP Processing In Vitro and In Vivo

V. Lee, M. Milla, Bin Zhang, 2008, The Journal of Neuroscience.

The cytoplasmic domain of myelin glycoprotein P0 interacts with negatively charged phospholipid bilayers.

Y. Ding, K. Brunden, Yungao Ding, 1994, The Journal of biological chemistry.

The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice

J. Trojanowski, V. Lee, S. Xie, 2012, The Journal of Neuroscience.

Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy

J. Trojanowski, V. Lee, S. Xie, 2010, The Journal of Neuroscience.

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

J. Trojanowski, V. Lee, K. Brunden, 2009, Nature Reviews Drug Discovery.

Dependence of the conformation of a colicin E1 channel-forming peptide on acidic pH and solvent polarity.

W. Cramer, K. Brunden, Y. Uratani, 1984, The Journal of biological chemistry.

Dependence of the activity of colicin E1 in artificial membrane vesicles on pH, membrane potential, and vesicle size.

V. Davidson, W. Cramer, K. Brunden, 1984, The Journal of biological chemistry.

Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP‐1 Cells and Murine Microglia

S. L. Yates, K. Brunden, L. H. Burgess, 2000, Journal of neurochemistry.

Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: Complement activation and therapeutic approaches

K. Brunden, R. Frederickson, Suio Chen, 1996, Neurobiology of Aging.

β-Amyloid induces increased release of interleukin-1β from lipopolysaccharide-activated human monocytes

K. Brunden, D. Lorton, L. King, 1996, Journal of Neuroimmunology.

Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells

J. Trojanowski, K. Luk, Cheng Song, 2009, Proceedings of the National Academy of Sciences.

Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.

J. Trojanowski, V. Lee, A. Brancale, 2014, ACS medicinal chemistry letters.

Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy

J. Trojanowski, V. Lee, R. Valentino, 2011, The Journal of Neuroscience.

Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease

J. Trojanowski, V. Lee, K. Luk, 2019, Neurobiology of Disease.

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

J. Trojanowski, V. Lee, A. Cacace, 2015, PloS one.

The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.

J. Trojanowski, V. Lee, Michael J. James, 2011, Pharmacological research.

Response to Comments on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

D. Wesson, G. Landreth, J. Cirrito, 2013, Science.

The Dynamics and Turnover of Tau Aggregates in Cultured Cells

V. Lee, D. Moechars, A. Buist, 2016, The Journal of Biological Chemistry.

Studies on the mechanism of action of channel-forming colicins using artificial membranes

V. Davidson, F. S. Cohen, W. Cramer, 2005, The Journal of Membrane Biology.

Identification of a Novel Extracellular Cation-sensing G-protein-coupled Receptor*

L. Quarles, R. Mays, K. Brunden, 2005, Journal of Biological Chemistry.

Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit

R. Brookmeyer, D. Meier, M. Naylor, 2012, Alzheimer's & Dementia.

Amyloid Fibrils Activate Tyrosine Kinase-Dependent Signaling and Superoxide Production in Microglia

Douglas R. McDonald, G. Landreth, K. Brunden, 1997, The Journal of Neuroscience.

Amyloid β protein (Aβ) removal by neuroglial cells in culture

S. Younkin, K. Brunden, R. Frederickson, 1995, Neurobiology of Aging.

Inflammatory responses to amyloid fibrils.

S. L. Yates, K. Brunden, P. Embury, 1999, Methods in enzymology.

Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays

J. Trojanowski, V. Lee, A. Zakharov, 2020, The Journal of Biological Chemistry.

A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research

M. Naylor, J. Trojanowski, J. Karlawish, 2012, Alzheimer's & Dementia.

EpothiloneDImprovesMicrotubuleDensity,Axonal Integrity,andCognitioninaTransgenicMouseModel ofTauopathy

K. Brunden, Y. Lee, 2010 .

Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease

John L. Robinson, J. Trojanowski, V. Lee, 2021, Acta Neuropathologica.

Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors

S. Xie, Katie Herbst-Robinson, Michael J. James, 2015, Scientific Reports.

Catabolic Regulation of the Expression of the Major Myelin Glycoprotein by Schwann Cells in Culture

A. Windebank, K. Brunden, J. Poduslo, 1990, Journal of neurochemistry.

Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors

J. Trojanowski, V. Lee, K. Brunden, 2010, Experimental Neurology.

Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments.

John Q Trojanowski, J. Trojanowski, V. Lee, 2008, Journal of Alzheimer's disease : JAD.

Amyloid beta protein (A beta) removal by neuroglial cells in culture.

S. Younkin, K. Brunden, R. Frederickson, 1995, Neurobiology of aging.

Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.

Ruili Huang, Christopher P Austin, Wenwei Huang, 2009, Biochemistry.

Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation*

J. Trojanowski, V. Lee, Michael J. James, 2013, The Journal of Biological Chemistry.

A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model

J. Trojanowski, V. Lee, Amos B. Smith, 2018, Molecular Neurodegeneration.

Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

J Q Trojanowski, A B Smith, J. Trojanowski, 2011, Current topics in medicinal chemistry.

Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs

J. Trojanowski, V. Lee, K. Brunden, 2017, Neurobiology of Disease.

Kinetics of production of a novel growth factor after peripheral nerve injury

A. Windebank, M. D. Blexrud, K. Brunden, 1990, Journal of the Neurological Sciences.

Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.

J. Trojanowski, V. Lee, Amos B. Smith, 2010, Journal of medicinal chemistry.

The complement cascade in Alzheimer's disease.

W. Benzing, K. Brunden, 1998, Drug News and Perspectives.

Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy

J. Trojanowski, V. Lee, Amos B. Smith, 2016, Acta neuropathologica communications.

Deposits of Aβ fibrils are not toxic to cortical and hippocampal neurons in vitro

K. Brunden, R. Frederickson, J. Wujek, 1996, Neurobiology of Aging.

A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model

J. Trojanowski, V. Lee, Amos B. Smith, 2018, Molecular Neurodegeneration.

Identification of novel and improved antimitotic agents derived from noscapine.

S. Rundlett, K. Brunden, A. Raber, 2005, Journal of medicinal chemistry.

Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497

J. Trojanowski, V. Lee, Amos B. Smith, 2014, Expert Opinion on Therapeutic Patents.

Abundant copathologies of polyglucosan bodies, frontotemporal lobar degeneration with TDP‐43 inclusions and ageing‐related tau astrogliopathy in a family with a GBE1 mutation

J. Trojanowski, M. Grossman, V. Lee, 2022, Neuropathology and applied neurobiology.

Preclinical characterization and IND‐enabling safety studies for PNT001, an antibody that recognizes cis‐pT231 tau

J. Trojanowski, M. Ahlijanian, L. Goldstein, 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Structure-Activity Relationships, Tolerability and Efficacy of Microtubule-Active 1,2,4-Triazolo[1,5-a]pyrimidines as Potential Candidates to Treat Human African Trypanosomiasis

A. Brancale, C. Caffrey, K. Brunden, 2023, bioRxiv.

Discovery of S-phase arresting agents derived from noscapine.

S. Rundlett, K. Brunden, A. Raber, 2005, Journal of medicinal chemistry.

Lysosomal delivery of the major myelin glycoprotein in the absence of myelin assembly: posttranslational regulation of the level of expression by Schwann cells

K. Brunden, J. Poduslo, Joseph E Poduslo, 1987, The Journal of cell biology.

The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists.

B. Huck, K. Brunden, J. Harrington, 2006, Bioorganic & medicinal chemistry letters.

Microtubule-Stabilizing 1,2,4-Triazolo[1,5-a]pyrimidines as Candidate Therapeutics for Neurodegenerative Disease: Matched Molecular Pair Analyses and Computational Studies Reveal New Structure–Activity Insights

Virginia M. Y. Lee, A. Brancale, Amos B. Smith, 2022, Journal of medicinal chemistry.

Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.

D. Hanniford, B. Sherf, K. Brunden, 2005, Assay and drug development technologies.

beta-Amyloid induces increased release of interleukin-1 beta from lipopolysaccharide-activated human monocytes.

K. Brunden, D. Lorton, L. King, 1996, Journal of neuroimmunology.

Identification of small molecules and related targets that modulate tau pathology in a seeded primary neuron model

Virginia M. Y. Lee, K. Brunden, Garrett S. Gibbons, 2023, The Journal of biological chemistry.

A microtubule stabilizer ameliorates protein pathogenesis and neurodegeneration in mouse models of repetitive traumatic brain injury

J. Trojanowski, T. Saido, Jennifer D. McBride, 2023, Science Translational Medicine.

J. Trojanowski, V. Lee, Amos B. Smith, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs

J. Trojanowski, V. Lee, K. Brunden, 2017, Neurobiology of Disease.

Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.

J. Trojanowski, V. Lee, K. Brunden, 2012, Biochemical Society transactions.

Response to Comments on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

D. Wesson, G. Landreth, J. Cirrito, 2013, Science.

MSUT2 regulates tau spreading via adenosinergic signaling mediated ASAP1 pathway in neurons

J. Trojanowski, B. Kraemer, K. Brunden, 2024, Acta neuropathologica.

A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease

K. Brunden, C. Ballatore, Bobby Lucero, 2024, Alzheimer's & dementia : the journal of the Alzheimer's Association.